Objective: To study the state of lipid metabolism in PD patients with concomitant type 2 diabetes with different glucose tolerance and the influence of the DA agonist receptor- bromocriptine(BC) on the clinical features of the disease.

Background: Polyetiological age-dependent diseases include(PD) and (DM) type 2.It is established that patients with PD and DM occur in 8.01% of cases (aged 40-59years-3.3%,aged60-70-10.6%,71-90years -9.5 %).

Methods: Examined 94 PD patients at the age of 45-65 years with stage of disease 1.5-3.0 by Hoehn and Yahr.63 patients were treated with (BC) at 7.5 mg /day for 25 days with basic antiParkinsonian therapy.The patients were divided into three groups:Group I – normal glucose tolerance(n = 45),II group-impaired glucose tolerance(IGT) (n =22),group III – concomitant with type 2 DM (n =27).Status of lipid spectrum was assessed by blood concentrations of total cholesterol (TC), low cholesterol (LDC) and high (HDC) density,triglycerides (TG), apolipoprotein (AP); atherogenic index was calculated (AI).

Results: Studies have shown that treatment with (BC) contributes to a significant improvement in lipid metabolism, especially in patients in II and III groups. Thus, the TC level decreased by 10.7% in Group II and by 12.5% in group III. The concentration of LDC in patients of I group decreased by 5%,group II-28.6%, III group by 18.2%.Noteworthy increase in anti-atherogenic HDC in the blood plasma of patients with PD:in the I group- 24%, in the II- 26%,in the III- 25%.As expected,the most significant decrease concentration of triglycerides after a course of treatment with (BC) revealed in patients with IGT (24.2%) and in patients with concomitant type 2 DM (25.1%)Reducing the concentration of AP on a background of treatment with (BC) was particularly pronounced in patients in II and III groups.Reducing the total cholesterol and increasing HDC after treatment with (BC) reduced the AI (in the I group – by 33.5%, in II – 24.5%, in the III – 33.8%),which significantly reduces the risk of vascular disease.

Conclusions: Course (BC) treatment not only normalized the lipid metabolism,but also significantly improved the neurological status of patients.The data obtained allow to recommend DA receptor agonists as the drugs of choice in the differentiated treatment of patients with PD with IGT at all stages of the disease for the prevention of vascular lesions of the brain.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-differentiated-treatment-of-parkinsons-disease-in-patients-with-concomitant-diabetes-mellitusdm-type-2/